Related Experiment Video
Updated: Aug 11, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Sirolimus: a new immunosuppressant
1PD Hinduja National Hospital and Medical Research Centre, Veer Savarkar Marg, Mahim, Mumbai 400 016, India.
The Journal of the Association of Physicians of India
|February 8, 2006
Summary
Organ transplantation faces rejection challenges. Sirolimus, a novel immunosuppressant, shows promise in preventing and treating organ rejection, with additional antifungal and antitumor benefits.
Area of Science:
- Immunology
- Pharmacology
- Transplantation Medicine
Background:
- Organ transplantation is a critical medical advancement but faces significant challenges with immune rejection.
- Current immunosuppressants like cyclosporine, azathioprine, and corticosteroids are effective but have notable adverse effects.
Purpose of the Study:
- To introduce Sirolimus, a novel immunosuppressant derived from a macrolide antibiotic.
- To explore the potential role of Sirolimus in managing organ transplant rejection.
- To highlight additional therapeutic properties of Sirolimus.
Main Methods:
- Review of existing literature on Sirolimus and its pharmacological properties.
- Analysis of Sirolimus's mechanism of action in the context of immunosuppression.
- Examination of preclinical and clinical data regarding Sirolimus efficacy.
Main Results:
- Sirolimus demonstrates potential efficacy in preventing organ transplant rejection.
- Sirolimus may be effective in treating refractory cases of organ transplant rejection.
- Sirolimus exhibits secondary benefits, including antifungal, antitumor, and anti-smooth muscle proliferative activities.
Conclusions:
- Sirolimus represents a promising new agent in the field of organ transplantation.
- Its multifaceted properties offer potential advantages over existing immunosuppressive therapies.
- Further research into Sirolimus is warranted to fully elucidate its therapeutic applications.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...